Pharsight

Chiesi patents expiration

1. Bethkis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7939502 CHIESI Optimised formulation of tobramycin for aerosolization
Jun, 2022

(1 year, 3 months ago)

US6987094 CHIESI Optimized formulation of tobramycin for aerosolization
Sep, 2022

(1 year, 11 days ago)

US7696178 CHIESI Optimised formulation of tobramycin for aerosolization
Sep, 2022

(1 year, 11 days ago)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 12 October, 2012

Treatment: Management of cystic fibrosis patients

Dosage: SOLUTION;INHALATION

How can I launch a generic of BETHKIS before it's drug patent expiration?
More Information on Dosage

BETHKIS family patents

Family Patents

2. Cardene patents expiration

CARDENE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE before it's drug patent expiration?
More Information on Dosage

CARDENE family patents

Family Patents

3. Cleviprex patents expiration

CLEVIPREX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage

CLEVIPREX family patents

Family Patents

4. Ferriprox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156 CHIESI Liquid formulation for deferiprone with palatable taste
Oct, 2029

(6 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11357731 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
Orphan Drug Exclusivity (ODE) Apr 30, 2028

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 09 September, 2015

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

More Information on Dosage

FERRIPROX family patents

Family Patents

5. Kengreal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6130208 CHIESI Formulation containing a nucleotide analogue
Jun, 2023

(3 months ago)

US9925265 CHIESI Methods of treating or preventing stent thrombosis
May, 2029

(5 years from now)

US9427448 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Nov, 2030

(7 years from now)

US8680052 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Mar, 2033

(9 years from now)

US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Jul, 2035

(11 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage

KENGREAL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic